Prodcuts
BioDiverseCores™ (BDCs ™):


CreaGen’s BDC program has collections of novel natural product and natural product-like scaffolds. Many of these scaffolds are target relevant cores that are designed to produce small molecule IP. These low molecular weight compounds are ideal for fragment-based screening. These cores have been designed with multiple diversity points to facilitate rapid synthesis of analogs that will provide SAR information. The multiple diversity points can also be be utilized to improve the pharmacokinetic properties of the target molecules such as solubility, bioavailability, selectivity and potency. CreaGen currently has 100 scaffolds in its BDC collection and continues to add approximately 25 new scaffolds per quarter. Our partners will have immediate access to our collections on a non-exclusive basis to develop potential new starting points for research programs.
 
News
  CreaGen Inc. makes into the 2018 list of major players in CRO industry
https://www.businesswire.com/news/home/20180412005808/en/Outsourcing-Drug-Discovery-Contract-Research-Organization-CRO https://themobileherald.com/contract-research-organization-market-industry-growth-and-forecast-analysis-report-till-2024/24870/ https://www.businesswire.com/news/home/20180412005808/en/Outsourcing-Drug-Discovery-Contract-Research-Organization-CRO   more...
    7th Advances In Chemical Sciences Symposium: May 4th, 2018
The Seventh Annual Advances in Chemical Sciences Symposium Royal Sonesta Hotel Cambridge, MA: May 4th, 2018 A day-long symposium focused on Medicinal Chemistry, Organic Synthesis, and Methodology, featuring eminent scientists from industry and academia. Speakers: Professor Richard R. Schrock (MIT): “TBA” Professor Dale L. Boger (Scripps Research Institute): “Redesign of Vancomycin for Resistant Bacteria” Professor Laura Kiessling (MIT): “TBA” Dr. Sue Ashwell (Forma Therapeutics): “Discovery and Optimization of a Novel Series of Inhibitors of mt-IDH1” Dr. Michael Hoemann (Abbvie): “Discovery and Optimization of Spleen Tyrosine Kinase Inhibitors for Immunological Diseases” Dr. Frank Salituro (Sage Therapeutics): “Discovery and Clinical Development of SAGE-217: A Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (GABA)A Receptor” Plus: Vendor Exhibition Hall and Networking Reception   more...
 
 
Home  |  About Us  |  Services  |  Products  |  R&D  |  News  |  Careers  |  Contact us Copyright © 2013 CreaGen Biosciences Inc. All rights reserved.